Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28371829 | 0.97 | HTT (0.33) | HTT | |
| SCHEMBL11416515 | 0.89 | TSHR (0.50) | HTTTSHR | |
| SCHEMBL6063631 | 0.77 | — | — | |
| SCHEMBL28854406 | 0.75 | PDE4A (0.52) | — | |
| SCHEMBL2968145 | 0.75 | PDE4A (0.52) | — | |
| SCHEMBL29043020 | 0.73 | PDE4A (0.50) | — | |
| SCHEMBL907805 | 0.73 | HTT (0.33) | HTTTSHR | |
| SCHEMBL524350 | 0.73 | — | — | |
| SCHEMBL3255288 | 0.73 | TSHR (0.31) | TSHR | |
| SCHEMBL1002608 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645829-B | Chiral synthesis method of ephedrine key intermediate (S) -2-methylamino-1-phenyl-1-acetone | 浙江普洛康裕制药有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-104755481-A | Solid salt forms of alpha-6-mPEG 6-O-hydroxycolone as opioid agonists and uses thereof | NEKTAR THERAPEUTICS | 2015-07-01 | — | — | CN | claimed |
| CN-102753540-B | α4β2Ligands for neuronal nicotinic acetylcholine receptors | SUVEN LIFE SCIENCES LTD | 2014-01-22 | — | — | CN | claimed |
| EP-2611444-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| CN-103079566-A | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LTD | 2013-05-01 | — | — | CN | claimed |
| CN-102020785-B | Compatilizer, application thereof in polyphenyleneoxide/nylon alloy and preparation method of polyphenyleneoxide/nylon alloy | UNIV HEBEI SCIENCE & TECH | 2013-02-13 | — | — | CN | claimed |
| CN-102753540-A | α4β2Ligands for neuronal nicotinic acetylcholine receptors | SUVEN LIFE SCIENCES LTD | 2012-10-24 | — | — | CN | claimed |
| WO-2012029070-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| CN-113710225-B | Delivery and retention of active agents within the skin | 范德生物公司 | 2024-06-21 | — | — | CN | disclosed |
| US-9975999-B2 | Liquid organopolysiloxane and uses thereof | DOW CORNING TORAY CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| CN-105237463-B | Preparation methods of one kind (3R, 4R) (base of 1 benzyl, 4 methyl piperidine 3) methylamine L bis- to toluoyltartrates | 刘卫国 | 2017-10-10 | — | — | CN | disclosed |
| CN-104755481-A | Solid salt forms of alpha-6-mPEG 6-O-hydroxycolone as opioid agonists and uses thereof | NEKTAR THERAPEUTICS | 2015-07-01 | — | — | CN | disclosed |
| US-8912179-B2 | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-12-16 | — | — | US | disclosed |
| US-20140364394-A1 | Novel Liquid Organopolysiloxane And Uses Thereof | DOW TORAY CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| CN-101257898-A | Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders | SEPRACOR INC (US) | 2008-09-03 | — | — | CN | disclosed |
| CN-101103029-A | 1,5,6-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-infective agents | TIBOTEC PHARM LTD (IE) | 2008-01-09 | — | — | CN | disclosed |
| CN-1208688-C | Polymers and positive photoresist compositions suitable for use as photoresists | AZ ELECTRONIC MATERIALS JAPAN (JP) | 2005-06-29 | — | — | CN | disclosed |
| CN-1530107-A | Insulin resistance treatment by growth hormone secretory hormone | �Ʒ� | 2004-09-22 | — | — | CN | disclosed |
| CN-1152049-C | Treatment of insulin resistance with growth hormone secretagogues | �Ʒ� | 2004-06-02 | — | — | CN | disclosed |
| CN-1305608-A | 193 NM wavelength positive-working photoresist composition | CLARIANT INT LTD (CH) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364394-A1 | Novel Liquid Organopolysiloxane And Uses Thereof | ALG1, SGMS1, LOXL1 | HTT 2372/4885TSHR 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.